Neurology

Journal

Publication Venue For

  • Prediction of Naming Outcome With FMRI Language Lateralization in Left Temporal Epilepsy Surgery.  98:E2337-E2346. 2022
  • Prognosis After Stroke: Do We Have What We Need to Talk With Patients and Their Families? 2022
  • Nucleosides Associated With Incident Ischemic Stroke in the REGARDS and JHS Cohorts.  98:E2097-E2107. 2022
  • Impact of Telestroke Implementation on Emergency Department Transfer Rate.  98:E1617-E1625. 2022
  • Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.  98:E376-E389. 2022
  • Disparities of Care in Post-Concussive Pediatric Patients.  98:S13. 2022
  • Efficacy of Outpatient Infusion Therapy in Pediatric Patients With Post-Concussive Headaches.  98:S14-S15. 2022
  • Evaluation of Sports-Related Concussion in Children (5-12) and Adolescents (13-18).  98:S12-S13. 2022
  • Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?.  98:12-13. 2022
  • Representation of Women in Stroke Clinical Trials: A Review of 281 Trials Involving More Than 500,000 Participants.  97:e1768-e1774. 2021
  • Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.  97:e1757-e1767. 2021
  • Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.  97:E1560-E1570. 2021
  • Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.  97:e1334-e1342. 2021
  • Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.  97:S15-S24. 2021
  • Sex and Race Differences in the Risk of Ischemic Stroke Associated With Fasting Blood Glucose in REGARDS.  97:e684-e694. 2021
  • Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.  97:S42-S49. 2021
  • Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study.  97:e436-e443. 2021
  • Neighborhood Socioeconomic Status and Stroke Incidence: A Systematic Review.  96:897-907. 2021
  • Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration.  96:e2296-e2312. 2021
  • Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.  96:e2313-e2322. 2021
  • Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy: CISP-Plus.  96:e2078-e2089. 2021
  • Association of De Novo RNF213 Variants With Childhood Onset Moyamoya Disease and Diffuse Occlusive Vasculopathy.  96:e1783-e1791. 2021
  • Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults.  96:e964-e974. 2021
  • Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort.  96:e563-e574. 2021
  • Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.  96:e632-e639. 2021
  • Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.  96:e214-e227. 2021
  • Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.  96:e111-e120. 2021
  • Racial Differences in Atrial Cardiopathy Phenotypes in Ischemic Stroke Patients. 2020
  • Bing-Neel syndrome mimicking a meningioma.  95:838-839. 2020
  • Pediatric Multiple Sclerosis Severity Score in a large US cohort.  95:e1844-e1853. 2020
  • Cardiovascular risk factors and accelerated cognitive decline in midlife: The CARDIA Study.  95:e839-e846. 2020
  • Minimal manifestation status and prednisone withdrawal in the MGTX trial.  95:e755-e766. 2020
  • Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.  95:e446-e456. 2020
  • The CREST-2 experience with the evolving challenges of COVID-19: A clinical trial in a pandemic.  95:29-36. 2020
  • Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials.  94:e2384-e2395. 2020
  • Author response: Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study.  94:636. 2020
  • Defining research priorities in dystonia.  94:526-537. 2020
  • Phrenic neuropathy water immersion dyspnea: Clinical findings and need for patient counseling.  94:e1314-e1319. 2020
  • Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.  94:481-494. 2020
  • Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.  94:495-500. 2020
  • Child Neurology: Arterial ischemic stroke in a 12-year-old patient with cardiac myxomas.  94:e1103-e1106. 2020
  • Unraveling the risk factors for spontaneous intracerebral hemorrhage among West Africans.  94:e998-e1012. 2020
  • Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.  93:e1452-e1462. 2019
  • Child Neurology: Spastic paraparesis and dystonia with a novel ADCY5 mutation.  93:510-514. 2019
  • Hand stereotypies: Lessons from the Rett Syndrome Natural History Study.  92:E2594-E2603. 2019
  • Reader response: Alien hand syndrome.  92:1070. 2019
  • Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort.  92:E2375-E2384. 2019
  • How should we normalize regional volume abnormalities in childhood neurodegenerative disorders?.  92:779-780. 2019
  • Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.  92:E1912-E1925. 2019
  • A survey of risk tolerance to multiple sclerosis therapies.  92:E1634-E1642. 2019
  • Dietary patterns during adulthood and cognitive performance in midlife: The CARDIA study.  92:E1589-E1599. 2019
  • A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.  92:469-480. 2019
  • The prevalence of MS in the United States: A population-based estimate using health claims data.  92:E1029-E1040. 2019
  • Serum magnesium and calcium levels in relation to ischemic stroke: Mendelian randomization study.  92:E944-E950. 2019
  • Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.  92:329-337. 2019
  • Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program.  92:e274-e280. 2019
  • Teaching neuroimages: Facial swelling and intracerebral hemorrhage from venous hypertension in a dialysis patient.  92:E521-E522. 2019
  • Word comprehension in temporal cortex and Wernicke area: A PPA perspective.  92:E224-E233. 2019
  • Clinical and neural responses to cognitive behavioral therapy for functional tremor.  93:1-12. 2019
  • PCNT point mutations and familial intracranial Aneurysms.  91:E2170-E2181. 2018
  • Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality.  91:E1741-E1750. 2018
  • Sleep duration and risk of incident stroke by age, sex, and race the REGARDS study.  91:E1702-E1709. 2018
  • Outcomes after carotid endarterectomy among elderly dual Medicare-Medicaid-eligible patients.  91:E1553-E1558. 2018
  • Clinical trial design for cutaneous neurofibromas.  91:S31-S37. 2018
  • Cutaneous neurofibromas: Current clinical and pathologic issues.  91:S5-S13. 2018
  • New diagnosis of cancer and the risk of subsequent cerebrovascular events.  90:E2025-E2033. 2018
  • Cerebellar volume as an imaging marker of development in infants with tuberous sclerosis complex..  90:e1493-e1500. 2018
  • Diet quality is associated with disability and symptom severity in multiple sclerosis.  90:E1-E11. 2018
  • MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study.  90:E264-E272. 2018
  • Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression.  89:1594-1603. 2017
  • Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression.  89:1594-1603. 2017
  • Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.  89:1429-1430. 2017
  • Child Neurology: Childhood basilar artery occlusion and stroke.  89:e68-e70. 2017
  • Author response: Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.  89:640-641. 2017
  • Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial.  89:355-362. 2017
  • Body mass index and outcome after revascularization for symptomatic carotid artery stenosis.  88:2052-2060. 2017
  • Child Neurology: LAMA2 muscular dystrophy without contractures.  88:e199-e203. 2017
  • Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment.  88:2026-2035. 2017
  • Clinical Reasoning: A 45-year-old man with weakness and myalgia after orthopedic surgery.  88:e185-e189. 2017
  • Racial differences in statin adherence following hospital discharge for ischemic stroke.  88:1839-1848. 2017
  • Evidence for a causal relationship between low Vitamin D, high BMI, and pediatric-onset MS.  88:1623-1629. 2017
  • High hypothetical interest in physician-assisted death in multiple sclerosis.  88:1528-1534. 2017
  • Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.  88:1197-1205. 2017
  • Child Neurology: Rocky Mountain spotted fever encephalitis.  88:e92-e95. 2017
  • Long-term functional outcome in patients with acquired infections after acute spinal cord injury.  88:892-900. 2017
  • Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy.  88:395-402. 2017
  • A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.  88:152-159. 2017
  • Neonatal seizures in premature infants with IVH: are myoclonic jerks seizures?.  88:92-95. 2017
  • Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.  87:2575-2584. 2016
  • Effect of aphasia on acute stroke outcomes.  87:2348-2354. 2016
  • Neighborhood socioeconomic index and stroke incidence in a national cohort of blacks and whites.  87:2340-2347. 2016
  • Twelve-month recovery of medical decision-making capacity following traumatic brain injury.  87:1052-1059. 2016
  • Pediatric multiple sclerosis Clinical features and outcome.  87:S74-S81. 2016
  • Symptom profiles of autism spectrum disorder in tuberous sclerosis complex.  87:766-772. 2016
  • Current status and recommendations for biomarkers and biobanking in neurofibromatosis.  87:S40-S48. 2016
  • Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort.  87:595-600. 2016
  • Health insurance affects the use of disease-modifying therapy in multiple sclerosis.  87:365-374. 2016
  • Recommendations for observational studies of comorbidity in multiple sclerosis..  86:1446-1453. 2016
  • The challenge of comorbidity in clinical trials for multiple sclerosis..  86:1437-1445. 2016
  • Hostile attitudes and effortful coping in young adulthood predict cognition 25 years later.  86:1227-1234. 2016
  • Differences in the role of black race and stroke risk factors for first vs recurrent stroke.  86:637-642. 2016
  • Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.  86:245-252. 2016
  • New-onset refractory status epilepticus.  85:1604-1613. 2015
  • Author response.  85:742-743. 2015
  • Emerging Subspecialties in Neurology: Neurorehabilitation.  85:e50-e52. 2015
  • DNA methylation slows effects of C9orf72 mutations.  84:1616-1617. 2015
  • Ictal adipokines are associated with pain severity and treatment response in episodic migraine.  84:1409-1418. 2015
  • Marijuana Usage and Disability in MS in the NARCOMS Registry.  April 06, 2015; 84 (14 Supplement):P1.140-P1.140. 2015
  • Long-term impact of stroke on family caregiver well-being: A population-based case-control study.  84:1323-1329. 2015
  • Differences in Alzheimer disease clinical trial outcomes based on age of the participants.  84:1121-1127. 2015
  • Placebo effect of medication cost in Parkinson disease: A randomized double-blind study.  84:794-802. 2015
  • Quality improvement in neurology: primary headache quality measures..  84:200-203. 2015
  • Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease..  83:1906-1913. 2014
  • Clinical response to Bevacizumab in schwannomatosis.  83:1986-1987. 2014
  • Protective environmental factors for neuromyelitis optica.  83:1923-1929. 2014
  • ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort.  83:1271-1276. 2014
  • JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene..  83:727-732. 2014
  • Defining the clinical course of multiple sclerosis: The 2013 revisions.  83:278-286. 2014
  • Spectrogram screening of adult EEGs is sensitive and efficient.  83:56-64. 2014
  • Paroxysmal hypnogenic dyskinesia.  82:1935. 2014
  • Feasibility of Huntington disease trials in the disease prodrome.  82:824-825. 2014
  • Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) trial.  82:744-751. 2014
  • Mortality in patients with multiple sclerosis.  81:184-192. 2013
  • Report of stroke-like symptoms predicts incident cognitive impairment in a stroke-free cohort.  81:113-118. 2013
  • Management of carotid stenosis in women consensus document.  80:2258-2268. 2013
  • Cerebral hemodynamics and cognitive decline: Swimming against the current.  80:2086-2087. 2013
  • Pearls and Oy-sters: Acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura.  80. 2013
  • Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis.  80:1771-1777. 2013
  • Adherence to a Mediterranean diet and risk of incident cognitive impairment.  80:1684-1692. 2013
  • Effect of duration and age at exposure to the Stroke Belt on incident stroke in adulthood.  80:1655-1661. 2013
  • Disability in multiple sclerosis: A reference for patients and clinicians.  80:1018-1024. 2013
  • Functional impairment in progressive supranuclear palsy.  80:380-384. 2013
  • Recommendations for imaging tumor response in neurofibromatosis clinical trials..  81. 2013
  • Assessment of cortical and striatal involvement in 523 Huntington disease brains.  79:1708-1715. 2012
  • Growth failure and outcome in Rett syndrome: Specific growth references.  79:1653-1661. 2012
  • Racial differences in albuminuria, kidney function, and risk of stroke.  79:1686-1692. 2012
  • What is it about neighborhood characteristics that influence survival after a stroke or TIA?.  79:1190-1191. 2012
  • Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis.  79:981-987. 2012
  • Novel late-onset Alzheimer disease loci variants associate with brain gene expression..  79:221-228. 2012
  • Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).  79:163-169. 2012
  • Treatment consent capacity in patients with traumatic brain injury across a range of injury severity.  78:1472-1478. 2012
  • Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study.  78:1434-1440. 2012
  • Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.  78:1315-1322. 2012
  • CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.  78:690-695. 2012
  • Incidence and prevalence of epilepsy among older US Medicare beneficiaries.  78:448-453. 2012
  • Carotid stenosis: To revascularize, or not to revascularize: That is the question.  78:294. 2012
  • Carotid stenosis: to revascularize, or not to revascularize: that is the question..  78:294. 2012
  • Cerebral hemodynamics and cognitive impairment: Baseline data from the RECON trial.  78:250-255. 2012
  • Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis.  77:2089-2096. 2011
  • Reply from the authors.  77. 2011
  • Clinical severity and quality of life in children and adolescents with Rett syndrome.  77:1812-1818. 2011
  • Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).  77:1801-1807. 2011
  • Vascular risk factors and cognitive impairment in a stroke-free cohort.  77:1729-1736. 2011
  • To the editor.  77. 2011
  • A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS..  77:1551-1560. 2011
  • GFAP mutations, age at onset, and clinical subtypes in Alexander disease.  77:1287-1294. 2011
  • Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS.  77:138-144. 2011
  • Common viruses associated with lower pediatric multiple sclerosis risk.  76:1989-1995. 2011
  • Behavioral therapy to treat urinary incontinence in Parkinson disease.  76:1631-1634. 2011
  • Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.  76:1222-1228. 2011
  • NMO Spectrum Disorder in Children and Adolescents.  76:A395-A396. 2011
  • Pituitary Adenoma Complicated By Multifocal Fibrosclerosis Involving Sella and Retroperitoneum.  76:A250-A251. 2011
  • Recurrent Demyelinating Events Following Pediatric Optic Neuritis (pON).  76:A394-A394. 2011
  • Racial and geographic differences in fish consumption: The regards study.  76:154-158. 2011
  • Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis.  75:2097-2102. 2010
  • Association of reversed Robin Hood syndrome with risk of stroke recurrence.  75:2003-2008. 2010
  • A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.  75:1189-1194. 2010
  • A case of neurosarcoidosis successfully treated with rituximab.  75:568-570. 2010
  • Reply from the authors.  74:1554-1555. 2010
  • Epilepsy and the natural history of Rett syndrome.  74:909-912. 2010
  • 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men.  74:33-41. 2010
  • Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.  74:1041-1047. 2010
  • Younger children with MS have a distinct CSF inflammatory profile at disease onset.  74:399-405. 2010
  • Association of higher diastolic blood pressure levels with cognitive impairment.  73:589-595. 2009
  • Reply from the authors.  73:571. 2009
  • Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS Research Participants.  73:385-392. 2009
  • Subthalamic nucleus and its connections: Anatomic substrate for the network effects of deep brain stimulation.  72:1110. 2009
  • Depression in Pediatric MS Patients Correlates with Increased Disease Severity and Selective Neuropsychological Deficits.  72:A371-A372. 2009
  • Hepatitis vaccines and pediatric multiple sclerosis: Does timing or type matter?.  72:870-871. 2009
  • Personality and lifestyle in relation to dementia incidence.  72:253-259. 2009
  • Comorbidity delays diagnosis and increases disability at diagnosis in MS.  72:117-124. 2009
  • A cross-sectional study of bone health in multiple sclerosis.  73:1394-1398. 2009
  • Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study.  73:928-934. 2009
  • Declining financial capacity in patients with MCI: A one-year longitudinal study.  73:928-934. 2009
  • Editorial: Relapses in multiple sclerosis: Important or not?.  73:1612-1613. 2009
  • Medical decision-making capacity in patients with malignant glioma.  73:2086-2092. 2009
  • Optic neuropathy in patients with glioblastoma receiving bevacizumab.  73:1924-1926. 2009
  • Invited Article: The US health care system: Part 1: Our current system.  71:1907-1913. 2008
  • Invited article: The US health care system: Part 2: Proposals for improvement and comparison to other systems.  71:1914-1920. 2008
  • Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis: Reply.  71:1747-1748. 2008
  • A novel PRNP-P105S mutation associated with atypical prion disease and a rare PrPSc conformation.  71:1431-1438. 2008
  • CNS aquaporin-4 autoimmunity in children.  71:93-100. 2008
  • Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study.  71:28-34. 2008
  • Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment.  70:1134-1140. 2008
  • Investigating genotype-phenotype relationships in Rett syndrome using an international data set.  70:868-875. 2008
  • Responsiveness and predictive values in PPMS: An uncertain message.  70:1061-1062. 2008
  • Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome.  70:1313-1321. 2008
  • Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: Redefining DYT14 as DYT5.  70:1377-1383. 2008
  • Erratum: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurology (2007) 68, (272-276)).  69:617. 2007
  • Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations.  69:640-643. 2007
  • Higher IgG index found in African Americans versus Caucasians with multiple sclerosis.  69:68-72. 2007
  • MR tractography depicting damage to the arcuate fasciculus in a patient with conduction aphasia [6].  69:321. 2007
  • Disparities in the management of multiple sclerosis-related bladder symptoms.  68:1971-1978. 2007
  • Migraine and retinal microvascular abnormalities: The Atherosclerosis Risk in Communities Study.  68:1694-1700. 2007
  • Predictors of diagnosis in Huntington disease.  68:1710-1717. 2007
  • Nothing out of sequence? Think deletion!.  68:975-976. 2007
  • Reply from the authors [8].  68:965. 2007
  • NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight.  68:643-647. 2007
  • A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.  68:20-28. 2007
  • Acute disseminated encephalomyelitis.  68. 2007
  • Clinical features of children and adolescents with multiple sclerosis.  68. 2007
  • Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy.  68:364-368. 2007
  • MRI features of pediatric multiple sclerosis.  68. 2007
  • Optical coherence tomography and disease subtype in multiple sclerosis.  69:2085-2092. 2007
  • Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.  68:272-276. 2007
  • Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (Neurolgy (2007) 68, (272-276)).  69:2187. 2007
  • Relation of vision to global and regional brain MRI in multiple sclerosis.  69:2128-2135. 2007
  • Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis.  69:1603-1609. 2007
  • Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD study.  67:2206-2210. 2006
  • Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease.  67:1592-1599. 2006
  • The Motor Activity Log-28: Assessing daily use of the hemiparetic arm after stroke.  67:1189-1194. 2006
  • Early progressive encephalopathy in boys and MECP2 mutations.  67:164-166. 2006
  • Quality improvement in acute stroke: The New York State Stroke Center Designation Project.  67:88-93. 2006
  • Elevated troponin levels are associated with higher mortality following intracerebral hemorrhage.  66:1330-1334. 2006
  • Does multiple sclerosis-associated disability differ between races?.  66:1235-1240. 2006
  • Futility studies: Spending a little to save a lot.  66:626-627. 2006
  • Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis [3].  66:954. 2006
  • A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.  66:664-671. 2006
  • Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis.  67:1288-1290. 2006
  • Perception of motor strength and stimulus magnitude are correlated in stroke patients.  66:1444-1446. 2006
  • BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.  65:1823-1825. 2005
  • Occupation and parkinsonism in three movement disorders clinics.  65:1430-1435. 2005
  • Changes in the ascertainment of multiple sclerosis.  65:1066-1070. 2005
  • MRI as a marker for disease heterogeneity in multiple sclerosis.  65:1071-1076. 2005
  • Frontotemporal dementia progresses to death faster than Alzheimer disease.  65:719-725. 2005
  • Does gender parity exist in Fabry disease?.  65:508-509. 2005
  • Blood harmane concentrations and dietary protein consumption in essential tremor.  65:391-396. 2005
  • Efficacy of rapid IV administration of valproic acid for status epilepticus [3] (multiple letters).  65:500-501. 2005
  • Medical decision-making in neurodegenerative disease: Mild AD and PD with cognitive impairment.  65:483-485. 2005
  • A clinical rating scale for Batten disease: Reliable and relevant for clinical trials.  65:275-279. 2005
  • Spinal fluid 5-methyltetrahydrofolate levels are normal in Rett syndrome.  64:2151-2152. 2005
  • Headache, cerebrovascular symptoms, and stroke: The atherosclerosis risk in communities study.  64:1573-1577. 2005
  • Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.  64:992-995. 2005
  • Unilateral cerebral peduncular atrophy progresses for decades after stroke.  64:A110-A110. 2005
  • Efficacy of rapid IV administration of valproic acid for status epilepticus.  64:353-355. 2005
  • Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology..  64:190-198. 2005
  • Training, competency, and credentialing standards for diagnostic cervicocerebral angiograpny, carotid stenting, and cerebrovascular intervention: A Joint Statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, and the Society of Interventional Radiology.  64:190-198. 2005
  • Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.  65:1941-1949. 2005
  • Intracranial arterial dolichoectasia is associated with enlarged descending thoracic aorta [1] (multiple letters).  65:1681-1682. 2005
  • Multifocal motor sensory demyelinating neuropathy: Inflammatory demyelinating polyradiculoneuropathy.  65:1639-1642. 2005
  • Pacemaker-induced tachycardia caused by inappropriate response to parkinsonian tremor.  65:1676-1677. 2005
  • Migraine and other headaches: Associations with Rose angina and coronary heart disease.  63:2233-2239. 2004
  • Cortical reorganization in malformations of cortical development: A magnetoencephalographic study.  63:1818-1824. 2004
  • The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson's disease.  63. 2004
  • Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease.  63:436-442. 2004
  • Disorganized search on cancellation is not a consequence of neglect.  63:78-84. 2004
  • Eclampsia, hippocampal sclerosis, and temporal lobe epilepsy: Accident or association?.  62:1352-1356. 2004
  • Ophthalmologic features of Parkinson's disease.  62:177-180. 2004
  • Frequency of epilepsy in patients with psychogenic seizures monitored by video-EEG.  61:1791-1792. 2003
  • A haplotype at the PARK3 locus influences onset age for Parkinson's disease: The GenePD study.  61:1557-1561. 2003
  • Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease..  61:S30-S31. 2003
  • Effect of relapses on development of residual deficit in multiple sclerosis.  61:1528-1532. 2003
  • II: A2A receptor modulation for symptomatic therapy in Parkinson's disease: Adenosine A2A receptor modulation of motor systems in PD.  61. 2003
  • Subacute inflammatory demyelinating polyneuropathy.  61:1507-1512. 2003
  • Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.  61:1367-1373. 2003
  • Teddy bears: An observational finding in patients with non-epileptic events.  61:714-715. 2003
  • A randomized controlled study of the acute and chronic effects of cooling therapy for MS..  60:1955-1960. 2003
  • Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.  60:1991-1992. 2003
  • A note of caution on correlation between sibling pairs [6] (multiple letters).  60:1561. 2003
  • Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease.  60:1189-1191. 2003
  • Predictors of nursing home placement in Huntington disease.  60:998-1001. 2003
  • Tic reduction with pergolide in a randomized controlled trial in children.  60:606-611. 2003
  • Tic reduction in Tourette Syndrome: improvement with pergolide in a randomized controlled trial in children.  60:606-611. 2003
  • Eight-year follow-up study of brain atrophy in patients with MS.  59:1412-1420. 2002
  • Weight loss in early stage of Huntington's disease.  59:1325-1330. 2002
  • Benefit of interferon β-1a on MSFC progression in secondary progressive MS.  59:679-687. 2002
  • Clinical and genetic heterogeneity in benign hereditary chorea.  59:579-584. 2002
  • Dopamine transmission in DYT1 dystonia: A biochemical and autoradiographical study.  59:445-448. 2002
  • Language lateralization in left-handed and ambidextrous people: fMRI data.  59:238-244. 2002
  • Molecular findings in symptomatic and pre-symptomatic Alexander disease patients.  58:1494-1500. 2002
  • Plexiform neurofibromas in NF1: Toward biologic-based therapy.  58:1461-1470. 2002
  • Porphyria presenting with bilateral radial motor neuropathy: Evidence of a novel gene mutation.  58:1118-1121. 2002
  • HLA-A2 homozygosity but not heterozygosity is associated with Alzheimer disease.  58:973-975. 2002
  • Depression associated with Parkinson's disease: Clinical features and treatment.  58. 2002
  • Treatment of ADHD in children with tics: A randomized controlled trial.  58:527-536. 2002
  • Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease.  58:362-367. 2002
  • Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults.  58:368-372. 2002
  • Epidemiologic study of 203 sibling pairs with Parkinson's disease: The GenePD study.  58:79-84. 2002
  • Genome-wide scan for Parkinson's disease: The GenePD study.  57:1124-1126. 2001
  • Bilateral hippocampal atrophy: Consequences to verbal memory following temporal lobectomy.  57:597-604. 2001
  • Chromosome 22q and the mind-brain interface: Bedside to bench to bedside.  57:377-378. 2001
  • Large-fiber neuropathy in distal sensory neuropathy with normal routine nerve conduction.  56:1570-1572. 2001
  • Parkinson's disease, CYP2D6 polymorphism, and age.  56:1363-1370. 2001
  • Use of the multiple sclerosis functional composite to predict disability in relapsing MS.  56:1324-1330. 2001
  • Left vagus nerve stimulation suppresses experimentally induced pain [3] (multiple letters).  56:985-986. 2001
  • Chronic thalamic stimulation for treatment of dystonic paroxysmal nonkinesigenic dyskinesia.  56:268-270. 2001
  • Postictal stability of proton magnetic resonance spectroscopy imaging (1H-MRSI) ratios in temporal lobe epilepsy.  56:251-253. 2001
  • Cardiovascular risk factors and cognitive decline in middle-aged adults.  56:42-48. 2001
  • Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease.  56:17-24. 2001
  • Sensory Guillain-Barré syndrome.  56:82-86. 2001
  • An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines.  56. 2001
  • Four-year incidence of psychogenic nonepileptic seizures in adults in Hamilton County, OH.  55:1561-1563. 2000
  • Pelizaeus-Merzbacher disease: Splice sites are nice sites for disease expression.  55:1072-1073. 2000
  • The experience of Wernicke's aphasia.  55:1222-1224. 2000
  • Low mini-mental status predicts mortality in asymptomatic carotid arterial stenosis.  55:30-34. 2000
  • Low mini-mental status predicts mortality in asymptomatic carotid arterial stenosis. Asymptomatic Carotid Atherosclerosis Study investigators..  55:30-34. 2000
  • Visual attention impairments in Alzheimer's disease.  54:1954-1959. 2000
  • Pure topographic disorientation: A distinctive syndrome with varied localization.  54:1864-1866. 2000
  • Enlarged parietal foramina: Association with cerebral venous and cortical anomalies.  54:1175-1178. 2000
  • Intrarater and interrater reliability of the MS functional composite outcome measure.  54:802-806. 2000
  • A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.  54:603-607. 2000
  • Arm levitation in progressive supranuclear palsy..  54:774. 2000
  • Rate of functional decline in Huntington's disease.  54:452-458. 2000
  • Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults [2] (multiple letters).  54:270-272. 2000
  • Pure topographic disorientation: A distinctive syndrome with varied localization.  54:575-578. 2000
  • Cognitive correlates of 1H MRSI-detected hippocampal abnormalities in temporal lobe epilepsy.  53:2052-2058. 1999
  • Error behaviors associated with loss of competency in Alzheimer's disease.  53:1983-1992. 1999
  • Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings.  53:2082-2087. 1999
  • Eliminating institutional child abuse: A road too well traveled.  53:1617-1621. 1999
  • Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset.  53:1868-1870. 1999
  • Neurologic complications of pediatric lung transplantation.  53:1542-1549. 1999
  • Subjective versus objective memory change after temporal lobe epilepsy surgery.  53:1511-1517. 1999
  • Evidence for the GluR6 gene associated with younger onset age of Huntington's disease.  53:1330-1332. 1999
  • Clinical and laboratory features of primary progressive and secondary progressive MS.  53:765-771. 1999
  • Cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis.  53:709-715. 1999
  • Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy.  53:687-694. 1999
  • Predictive value of 1H MRSI for outcome in temporal lobectomy.  53:694-698. 1999
  • Quantitative MRI in temporal lobe epilepsy: Evidence for fornix atrophy.  53:496-501. 1999
  • Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.  52:321-327. 1999
  • Temporal lobe developmental malformations and hippocampal sclerosis epilepsy surgical outcome.  52:479-484. 1999
  • Temporal lobe developmental malformations and hippocampal sclerosis: Epilepsy surgery outcome.  53:694-698. 1999
  • Lesion laterality, neglect, and anosognosia..  51:920-921. 1998
  • 1H NMR spectroscopy studies of Huntington's disease. Correlations with CAG repeat numbers.  50:1357-1365. 1998
  • A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis.  50:411-417. 1998
  • Age-related changes in the level of urinary myelin basic protein-like material during childhood.  51:1339-1341. 1998
  • Central poststroke pain and Wallenberg's lateral medullary infarction.  50:1521. 1998
  • Central poststroke pain associated with lateral medullary infarction.  50:837. 1998
  • Could pure alexia be due to a disconnection syndrome?.  50:835. 1998
  • Topiramate increases brain GABA in healthy adults.  51:627-629. 1998
  • Topiramate increases cerebral GABA in healthy humans.  51:627-629. 1998
  • Clearing up misunderstandings about clinical trial methodology: a reply to Barnett et al.'s commentary on the ACAS Trial. ACAS Executive Committee, ACAS Data and Safety Monitoring Committee..  48:1743-1745. 1997
  • Differential diagnosis of Alzheimer's disease.  48. 1997
  • Anterior translocation of language in patients with left cerebral arteriovenous malformation.  49:802-808. 1997
  • Central poststroke pain and Wallenberg's lateral medullary infarction: Frequency, character, and determinants in 63 patients.  49:120-125. 1997
  • Chromosome 17 and hereditary dementia: Linkage studies in three non- Alzheimer families and kindreds with late-onset FAD.  48:949-954. 1997
  • Clearing up misunderstandings about clinical trial methodology: A reply to Barnett et al.'s commentary on the ACAS trial [2] (multiple letters).  48:1743-1748. 1997
  • Congenital porencephaly and hippocampal sclerosis: Clinical features and epileptic spectrum.  49:1382-1388. 1997
  • Corticobasal degeneration: Neuropathologic and clinical heterogeneity.  48:959-969. 1997
  • Epilepsy surgery outcome: Comprehensive assessment in children.  48:1368-1374. 1997
  • Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease.  49:512-518. 1997
  • Hemianopic anosognosia.  49:88-97. 1997
  • Krabbe continuum or clinical conundrum?.  49:1203-1204. 1997
  • Oral phenylalanine loading in dopa-responsive dystonia: A possible diagnostic test.  48:1290-1297. 1997
  • The role of dopamine agonists in early Parkinson's disease.  49. 1997
  • Validation of the ACAS TIA/stroke algorithm.  48:346-351. 1997
  • Apolipoprotein E ∈4 association with dementia in a population-based study: The Framingham Study.  46:673-677. 1996
  • Increased risk of familial late-onset Alzheimer's disease in women.  46:126-129. 1996
  • Mutation of the prion protein gene at codon 208 in familial Creutzfeldt- Jakob disease.  47:1305-1312. 1996
  • Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways.  47:408-417. 1996
  • Reply from the Author: Gender and AD.  47:1358. 1996
  • Sorivudine: a promising drug for the treatment of varicella-zoster virus infection..  45:S73-S75. 1995
  • Circulating adhesion molecules and inflammatory mediators in demyelination: A review.  45:S22-S32. 1995
  • Cytokine localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species.  45:S16-S21. 1995
  • Familial progressive subcortical gliosis: Presence of prions and linkage to chromosome 17.  45:1062-1067. 1995
  • Genetic anticipation in parkinson's disease.  45:135-138. 1995
  • Inhibitory cytokines and cytokine inhibitors.  45:S39-S43. 1995
  • No evidence for association of familial parkinson's disease with cag repeat expansion.  45:1760-1763. 1995
  • Sorivudine: A promising drug for the treatment of varicella-zoster virus infection.  45:S73-S75. 1995
  • VISUAL PHENOMENA LIMITED TO THE HEMIANOPIC FIELD IN LESIONS OF THE CENTRAL VISUAL PATHWAYS.  44:A266-A266. 1994
  • A clinical genetic study of parkinson’s disease: Evidence for dominant transmission.  44:499-506. 1994
  • Progressive supranuclear palsy: Neuropathologic and clinical heterogeneity.  44:1015-1024. 1994
  • Capsular genu syndrome [7].  43:1862-1863. 1993
  • Chiari headaches.  43:1272. 1993
  • Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of huntington's disease: A quantitative golgi study.  43:2088-2096. 1993
  • Extrapersonal neglect [2].  43:1859-1860. 1993
  • Nonoptic aphasia: Aphasia with preserved confrontation naming in alzheimer's disease.  43:1900-1907. 1993
  • Left hemiparalexia..  42:562-569. 1992
  • A syndrome of autosomal dominant alternating hemiplegia: Clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations.  42:2251-2257. 1992
  • Confusion and memory loss from capsular genu infarction: A thalamocortical disconnection syndrome?.  42:1966-1979. 1992
  • Kynurenine pathway abnormalities in Parkinson's disease.  42:1702-1706. 1992
  • Left hemiparalexia.  42:562-569. 1992
  • Subacute necrotizing encephalopathy: Oxidative phosphorylation defects and the ATPase 6 point mutation.  42:2168-2174. 1992
  • MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria..  41:1300-1302. 1991
  • Clozapine is beneficial for psychosis in parkinson's disease.  41:1699-1700. 1991
  • Electrophysiologic analysis of early Parkinson’s disease.  41:44-48. 1991
  • HLA-A2, or a closely linked gene, confers susceptibility to early-onset sporadic alzheimer’s disease in mene.  41:1544-1548. 1991
  • Morphometric analysis of the prefrontal cortex in huntington’s disease.  41:1117-1123. 1991
  • Sagittal sinus thrombosis and leptomeningeal medulloblastoma.  41:455-456. 1991
  • United parkinson foundation neurotransplantation registry on adrenal medullary transplants: Presurgical, and 1– and 2–year follow–up.  41:1719-1722. 1991
  • Progressive aphasia: A precursor of global dementia? 1990
  • Bodily neglect and orientational biases in unilateral neglect syndrome and normal subjects.  40:640-643. 1990
  • Extrapyramidal involvement in Rett’s syndrome.  40:293-295. 1990
  • Multiple sclerosis sibling pairs: Clustered onset and familial predisposition.  40:1546-1552. 1990
  • Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q).  40:1831-1836. 1990
  • The intracarotid amobarbital procedure as a predictor of memory failure following unilateral temporal lobectomy.  40:605-610. 1990
  • Transmission and age-at-onset patterns in familial alzheimer’s disease: Evidence for heterogeneity.  40:395-403. 1990
  • Changes in survival after transient ischemic attacks: Observations comparing the 1970s and 1980s.  39:982-985. 1989
  • Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.  39:62-66. 1989
  • Ocular stroke and carotid artery dissection.  39:1462-1464. 1989
  • Phenotypic variation in 2 huntington’s disease families with linkage to chromosome 4.  39:1332-1336. 1989
  • Reply from the authors: Hemispatial neglect.  39:458. 1989
  • Reply from the authors: Hemispatial neglect.  39:1006. 1989
  • Seizures after primary intracerebral hemorrhage.  39:1089-1093. 1989
  • Clinical and neuropathologic assessment of severity in huntington’s disease.  38:341-347. 1988
  • Dopaminergic effects on simple and choice reaction time performance in Parkinson’s disease.  38:249-254. 1988
  • Hemispatial neglect affected by non-neglected stimuli.  38:1207-1211. 1988
  • Perseveration in behavioral neurology 1987
  • Aneurysmal compression of the anterior visual pathways.  36:1035-1041. 1986
  • Krabbe disease: Specific MRI and CT findings.  36:111-115. 1986
  • Dorsal midbrain syndrome in multiple sclerosis.  31:196-198. 1981
  • Transient ischemic attacks: A prospective study of 225 patients.  28:746-753. 1978
  • Metachromatic leukodystrophy: Comparison of early-and late-onset forms.  27:933-941. 1977
  • Metrizamide encephalography: The use of a new, CSF soluble contrast agent.  27:388. 1977
  • Stroke in a 15-year-old girl secondary to terminal carotid dissection.  25:725-729. 1975
  • Subarachnoid hemorrhage caused by rupture of a small superficial artery.  24:319-321. 1974
  • Neoplasms of the central nervous system: Epidemiologic considerations.  22:40-48. 1972
  • Peripheral nerve glycolipids in metachromatic leukodystrophy.  17:1033-1033. 1967
  • Steroid suppression of meningeal inflammation caused by pantopaque.  9:48-52. 1959
  • International Standard Serial Number (issn)

  • 0028-3878
  • 1526-632X
  • Electronic International Standard Serial Number (eissn)

  • 0028-3878
  • 1526-632X